Simple blood tests could spot liver damage early in diabetics
NCT ID NCT06567990
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study is testing whether simple blood tests and a liver scan can accurately track liver disease progression in 500 people with type 2 diabetes. Participants will be followed over time to see if these non-invasive tools can replace liver biopsies for detecting advanced scarring. The goal is to make screening easier and catch serious liver problems earlier.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Non-invasive blood tests and imaging (FibroScan)
- What this could lead to
- If successful, this could lead to better, simpler ways to detect liver disease progression early in people with type 2 diabetes, potentially preventing severe complications.
- What could go wrong
- This is an observational study, not a treatment trial. The biomarkers may not prove accurate enough to change clinical practice, and results may take years to confirm.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METABOLIC DYSFUNCTION-ASSOCIATED LIVER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Clinique d'Endocrinologie, Maladies Métaboliques et Nutrition CIC Endocrino-Nut
RECRUITINGNantes, 44093, France
-
Endocrinologie, Diabète et Nutrition in Louis PRADEL Hospital
RECRUITINGLyon, 69677, France
-
Service Endocrinologie, Diabétologie, Maladies Métaboliques et Nutrition
RECRUITINGDijon, BP 1542- 14, France
-
Service d'Endocrinologie, Diabète et nutrition
RECRUITINGPierre-Bénite, 69495, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.